Arnon Nagler, MD, MSc, is the Director of the Division of Hematology and the Bone Marrow Transplantation and Cord Blood Bank at the Chaim Sheba Medical Center, Tel Aviv, Israel, and is also a Professor of Medicine at Tel Aviv University, Tel Aviv, Israel.
Prof. Nagler completed his medical studies at the Hebrew University-Hadassah Medical School, Jerusalem, Israel, followed by a residency in internal medicine at the Rambam Medical Center, Haifa, Israel. He then obtained a master’s in hematopoiesis from Tel Aviv University, Tel Aviv, Israel, before moving to the US to complete his postdoctoral research fellowship in hematology and bone marrow transplantation at the Stanford University Hospital, Palo Alto, CA, qualifying in 1990.
Prof. Nagler is an active member of the European Group for Blood and Marrow Transplantation (EBMT) and serves on the Board of Directors of Netcord organization of cord blood banks.
Speaking on HSCT and hematological malignancies
Prof. Nagler’s work has involved investigating strategies to improve outcomes after hematopoietic stem cell transplantation (HSCT) and developing novel treatment strategies for hematological malignancies. His recent work has been on the use of reduced intensity conditioning before HSCT in patients with secondary acute myeloid leukemia (AML). Prof. Nagler has also recently been involved in a study investigating the safety and efficacy of a CD19/CD22 dual-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory aggressive B-cell lymphoma.